8r7g

From Proteopedia

(Difference between revisions)
Jump to: navigation, search
m (Protected "8r7g" [edit=sysop:move=sysop])
Current revision (07:38, 21 November 2024) (edit) (undo)
 
(2 intermediate revisions not shown.)
Line 1: Line 1:
-
'''Unreleased structure'''
 
-
The entry 8r7g is ON HOLD
+
==Crystal structure of the kinase domain of ACVR1 (ALK2) with M4K2234==
 +
<StructureSection load='8r7g' size='340' side='right'caption='[[8r7g]], [[Resolution|resolution]] 2.09&Aring;' scene=''>
 +
== Structural highlights ==
 +
<table><tr><td colspan='2'>[[8r7g]] is a 4 chain structure with sequence from [https://en.wikipedia.org/wiki/Homo_sapiens Homo sapiens]. Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=8R7G OCA]. For a <b>guided tour on the structure components</b> use [https://proteopedia.org/fgij/fg.htm?mol=8R7G FirstGlance]. <br>
 +
</td></tr><tr id='method'><td class="sblockLbl"><b>[[Empirical_models|Method:]]</b></td><td class="sblockDat" id="methodDat">X-ray diffraction, [[Resolution|Resolution]] 2.09&#8491;</td></tr>
 +
<tr id='ligand'><td class="sblockLbl"><b>[[Ligand|Ligands:]]</b></td><td class="sblockDat" id="ligandDat"><scene name='pdbligand=YEE:2-fluoranyl-6-methoxy-4-[4-methyl-5-[4-(4-propan-2-ylpiperazin-1-yl)phenyl]pyridin-3-yl]benzamide'>YEE</scene></td></tr>
 +
<tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[https://proteopedia.org/fgij/fg.htm?mol=8r7g FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=8r7g OCA], [https://pdbe.org/8r7g PDBe], [https://www.rcsb.org/pdb/explore.do?structureId=8r7g RCSB], [https://www.ebi.ac.uk/pdbsum/8r7g PDBsum], [https://prosat.h-its.org/prosat/prosatexe?pdbcode=8r7g ProSAT]</span></td></tr>
 +
</table>
 +
== Disease ==
 +
[https://www.uniprot.org/uniprot/ACVR1_HUMAN ACVR1_HUMAN] Fibrodysplasia ossificans progressiva. Defects in ACVR1 are a cause of fibrodysplasia ossificans progressiva (FOP) [MIM:[https://omim.org/entry/135100 135100]. FOP is a rare autosomal dominant disorder of skeletal malformations and progressive extraskeletal ossification. Heterotopic ossification in FOP begins in childhood and can be induced by trauma or may occur without warning. Bone formation is episodic and progressive, leading to extra-articular ankylosis of all major joints of the axial and appendicular skeleton, rendering movement impossible.<ref>PMID:16642017</ref> <ref>PMID:19085907</ref> <ref>PMID:19330033</ref>
 +
== Function ==
 +
[https://www.uniprot.org/uniprot/ACVR1_HUMAN ACVR1_HUMAN] On ligand binding, forms a receptor complex consisting of two type II and two type I transmembrane serine/threonine kinases. Type II receptors phosphorylate and activate type I receptors which autophosphorylate, then bind and activate SMAD transcriptional regulators. Receptor for activin. May be involved for left-right pattern formation during embryogenesis (By similarity).
 +
<div style="background-color:#fffaf0;">
 +
== Publication Abstract from PubMed ==
 +
Diffuse intrinsic pontine glioma is an aggressive pediatric cancer for which no effective chemotherapeutic drugs exist. Analysis of the genomic landscape of this disease has led to the identification of the serine/threonine kinase ALK2 as a potential target for therapeutic intervention. In this work, we adopted an open science approach to develop a series of potent type I inhibitors of ALK2 which are orally bio-available and brain-penetrant. Initial efforts resulted in the discovery of M4K2009, an analogue of the previously reported ALK2 inhibitor LDN-214117. Although highly selective for ALK2 over the TGF-betaR1 receptor ALK5, M4K2009 is also moderately active against the hERG potassium channel. Varying the substituents of the trimethoxyphenyl moiety gave rise to an equipotent benzamide analogue M4K2149 with reduced off-target affinity for the ion channel. Additional modifications yielded 2-fluoro-6-methoxybenzamide derivatives (26a-c), which possess high inhibitory activity against ALK2, excellent selectivity, and superior pharmacokinetic profiles.
-
Authors: Williams, E.P., Cros, J., Ensan, D., Smil, D., Edwards, A.M., O''Meara, J.A., Fernandez-Cid, A., Isaac, M.B., Al-awar, R., Bullock, A.N.
+
Targeting ALK2: An Open Science Approach to Developing Therapeutics for the Treatment of Diffuse Intrinsic Pontine Glioma.,Ensan D, Smil D, Zepeda-Velazquez CA, Panagopoulos D, Wong JF, Williams EP, Adamson R, Bullock AN, Kiyota T, Aman A, Roberts OG, Edwards AM, O'Meara JA, Isaac MB, Al-Awar R J Med Chem. 2020 May 5. doi: 10.1021/acs.jmedchem.0c00395. PMID:32369358<ref>PMID:32369358</ref>
-
Description: Crystal structure of the kinase domain of ACVR1 (ALK2) with M4K2234
+
From MEDLINE&reg;/PubMed&reg;, a database of the U.S. National Library of Medicine.<br>
-
[[Category: Unreleased Structures]]
+
</div>
-
[[Category: Fernandez-Cid, A]]
+
<div class="pdbe-citations 8r7g" style="background-color:#fffaf0;"></div>
-
[[Category: O''Meara, J.A]]
+
== References ==
-
[[Category: Edwards, A.M]]
+
<references/>
-
[[Category: Williams, E.P]]
+
__TOC__
-
[[Category: Cros, J]]
+
</StructureSection>
-
[[Category: Ensan, D]]
+
[[Category: Homo sapiens]]
-
[[Category: Isaac, M.B]]
+
[[Category: Large Structures]]
-
[[Category: Smil, D]]
+
[[Category: Al-awar R]]
-
[[Category: Bullock, A.N]]
+
[[Category: Bullock AN]]
-
[[Category: Al-Awar, R]]
+
[[Category: Cros J]]
 +
[[Category: Edwards AM]]
 +
[[Category: Ensan D]]
 +
[[Category: Fernandez-Cid A]]
 +
[[Category: Isaac MB]]
 +
[[Category: O'Meara JA]]
 +
[[Category: Smil D]]
 +
[[Category: Williams EP]]

Current revision

Crystal structure of the kinase domain of ACVR1 (ALK2) with M4K2234

PDB ID 8r7g

Drag the structure with the mouse to rotate

Proteopedia Page Contributors and Editors (what is this?)

OCA

Retrieved from "http://52.214.119.220/wiki/index.php/8r7g"
Personal tools